Clinical Research Directory
Browse clinical research sites, groups, and studies.
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Sponsor: Masaryk Memorial Cancer Institute
Summary
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.
Official title: Determination of Minimal Residual Disease by Deep ctDNA Sequencing.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2022-08-22
Completion Date
2026-12-31
Last Updated
2026-06-24
Healthy Volunteers
No
Interventions
NGS sequencing of mutations selected based on sequencing of primary tumors
Sequencing of the primary tumor will be performed on a MiSeq instrument using the Accel-Amplicon panel, which covers the most common mutations. For deep sequencing of ctDNA, 2-3 genomic regions carrying mutations in the primary tumor will be selected for the patient. For these regions, sets of universal primers will be designed to amplify the mutations most commonly found in solid tumors (RAS, BRAF, TP53, EGFR, APC, etc.). Another set of universal primers will contain a sequence for indexing individual samples, enabling the parallel sequencing of up to 96 samples simultaneously. The sequencing library will be analyzed on a NextSeq 500 instrument, which allows for up to 400 million reads in a single sequencing run. The sequencing results will then be correlated with the clinical course of the disease.
Locations (1)
Masaryk Memorial Cancer Institute
Brno, Czechia